Literature DB >> 7849244

Cyclosporine in the treatment of idiopathic nephrosis.

P Niaudet1, R Habib.   

Abstract

Within the past decade, there have been numerous reports on the use of cyclosporine in idiopathic nephrosis. In this review, the results of both uncontrolled and controlled studies of the therapeutic effects of cyclosporine in steroid-sensitive/dependent idiopathic nephrosis and in steroid-resistant idiopathic nephrosis are analyzed. Cyclosporine is efficient in up to 80% of patients with steroid-sensitive/dependent idiopathic nephrosis. Most patients, however, relapse when the drug is withdrawn, thus necessitating prolonged treatments. Although cyclosporine is less efficient in patients with steroid-resistant idiopathic nephrosis, a few studies seem to indicate that this drug may be successful in some patients, especially if combined with corticosteroids. There is no evidence that cyclosporine can prevent the recurrence of nephrotic syndrome on the graft after renal transplantation. However, in patients in whom disease has recurred, high doses of cyclosporine may be effective alone or in combination with plasma exchanges. The main worrisome side effect of cyclosporine is chronic nephrotoxicity, which should be differentiated from acute or "functional" toxicity. Follow-up studies including pretreatment and posttreatment renal biopsies show a lack of correlation between structural damage and renal function, suggesting that a histologic examination of the renal parenchyma is the only reliable way of evaluating chronic cyclosporine nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7849244     DOI: 10.1681/ASN.V541049

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  22 in total

1.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

2.  Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome.

Authors:  Aditi Sinha; Arvind Bagga; Ashima Gulati; Pankaj Hari
Journal:  Pediatr Nephrol       Date:  2011-09-16       Impact factor: 3.714

3.  Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment.

Authors:  Valérie Leroy; Véronique Baudouin; Corinne Alberti; Geneviève Guest; Patrick Niaudet; Chantal Loirat; Georges Deschenes; Paul Czernichow; Dominique Simon
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

4.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

5.  Co-administration of cyclosporine and ketoconazole in idiopathic childhood nephrosis.

Authors:  Amr el-Husseini; Fathy el-Basuony; Ihab Mahmoud; Ahmed Donia; Nabil Hassan; Nagy Sayed-Ahmad; Mohamed Sobh
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

6.  Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome.

Authors:  Severin Kengne-Wafo; Laura Massella; Francesca Diomedi-Camassei; Alessandra Gianviti; Marina Vivarelli; Marcella Greco; Gilda Rita Stringini; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 8.237

Review 7.  New perspectives in treatment of glomerulonephritis.

Authors:  Rosanna Coppo; Alessandro Amore
Journal:  Pediatr Nephrol       Date:  2003-12-13       Impact factor: 3.714

Review 8.  Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?

Authors:  Jörg Dötsch; Dirk E Müller-Wiefel; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2007-09-26       Impact factor: 3.714

9.  Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.

Authors:  Eiske M Dorresteijn; Joana E Kist-van Holthe; Elena N Levtchenko; Jeroen Nauta; Wim C J Hop; Albert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2008-07-12       Impact factor: 3.714

10.  Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis.

Authors:  Kerstin Benz; Kerstin Amann; Katalin Dittrich; Jörg Dötsch
Journal:  Pediatr Nephrol       Date:  2007-09-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.